A two-week interruption to methotrexate therapy can double the antibody response to COVID-19 booster vaccines in adults with immune-mediated inflammatory diseases, new research shows.

Although this short drug holiday was associated with more disease flare-ups, UK clinicians say most were self-managed and had no adverse impact on patient quality of life.